Anti-PDZRN4 抗体 [EPR11852] (ab171083)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR11852] to PDZRN4
- Suitable for: Flow Cyt (Intra), WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-PDZRN4 antibody [EPR11852]
PDZRN4 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR11852] to PDZRN4 -
由来種
Rabbit -
アプリケーション
適用あり: Flow Cyt (Intra), WB, IHC-Pmore details
適用なし: IP -
種交差性
交差種: Human
非交差種: Mouse, Rat -
免疫原
Recombinant fragment within Human PDZRN4. The exact sequence is proprietary.
Database link: Q6ZMN7 -
ポジティブ・コントロール
- Human prostate, HepG2 and U87-MG lysates; Human cervical carcinoma and lung carcinoma tissues; U87-MG cells.
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
バッファー
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: BSA, Glycerol (glycerin, glycerine) -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EPR11852 -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Isotype control
-
Positive Controls
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab171083の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Flow Cyt (Intra) |
1/100 - 1/500.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB |
1/1000 - 1/5000. Predicted molecular weight: 117 kDa.
|
|
IHC-P |
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
特記事項 |
---|
Flow Cyt (Intra)
1/100 - 1/500. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
WB
1/1000 - 1/5000. Predicted molecular weight: 117 kDa. |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
ターゲット情報
-
関連性
PDZRN4 (PDZ domain-containing RING finger protein 4) contains two PDZ (DHR) domains and a RING-type zinc finger. Its function is unknown. -
参照データベース
- Entrez Gene: 29951 Human
- Omim: 609730 Human
- SwissProt: Q6ZMN7 Human
-
別名
- 1110017D07Rik antibody
- IMAGE5767589 antibody
- KIAA3027 antibody
see all
画像
-
All lanes : Anti-PDZRN4 antibody [EPR11852] (ab171083) at 1/1000 dilution
Lane 1 : Human prostate tissue lysate
Lane 2 : HepG2 cell lysate
Lane 3 : U87-MG cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 117 kDa -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PDZRN4 antibody [EPR11852] (ab171083)
Immunohistochemical analysis of paraffin-embedded Human cervical carcinoma tissue labeling PDZRN4 with ab171083 at 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PDZRN4 antibody [EPR11852] (ab171083)
Immunohistochemical analysis of paraffin-embedded Human lung carcinoma tissue labeling PDZRN4 with ab171083 at 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Intracellular flow cytometric analysis of permeabilized U87-MG cells labeling PDZRN4 with ab171083 at 1/100 dilution (red), compared to arabbit IgG negative control (green).
プロトコール
データシートおよび資料
-
Datasheet download
参考文献 (1)
ab171083 は 1 報の論文で使用されています。
- Jin P et al. PDZRN4 suppresses tumorigenesis and androgen therapy-resistance in prostate cancer. J Cancer 13:2293-2300 (2022). PubMed: 35517421